Rifaximin oral tablet    (DrugBank: Rifaximin)

1 disease
IDDisease name (Link within this page)Number of trials
99Chronic intestinal pseudo-obstruction1

99. Chronic intestinal pseudo-obstruction    [ 3 clinical trials,   6 drugs,   (DrugBank: 1 drug),   0 drug target gene,   0 drug target pathway]
Searched query = "Chronic intestinal pseudo-obstruction", "Chronic idiopathic pseudo-bowel obstruction", "Chronic Idiopathic Intestinal Pseudo-Obstruction", "CIIP"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 3 trial found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04118699
(ClinicalTrials.gov)
December 25, 201923/9/2019Efficacy and Safety of Rifaximin for Patients With Chronic Intestinal Pseudo-obstruction: a Phase 2 TrialEfficacy and Safety of Rifaximin for Patients With Chronic Intestinal Pseudo-obstruction: a Single Center, Randomized, Placebo Controlled, Double-blind Phase 2 TrialChronic Intestinal Pseudo-obstructionDrug: Rifaximin oral tablet;Drug: Placebo oral tabletYokohama City UniversityASKA Pharmaceutical Co., Ltd.Recruiting20 Years74 YearsAll12Phase 2Japan